Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.13 CNY
−801.32 M CNY
1.21 M CNY
About CHONGQING GENRIX BIOPHARMACEUTICAL
Sector
CEO
Zhi Yuan Chang
Headquarters
Chongqing
Website
Founded
2015
ISIN
CNE100006KG8
FIGI
BBG018CDC7M6
Chongqing Genrix Biopharmaceutical Co., Ltd. principally engages in the research, development, production, and sale of antibody drugs. Its key antibody drugs are mainly for autoimmune diseases, infectious diseases, and tumors. The company was founded on October 20, 2015 and is headquartered in Chongqing, China.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 688443 is 26.25 CNY — it has decreased by −1.69% in the past 24 hours. Watch CHONGQING GENRIX BIOPHARMACEUTICAL stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SSE exchange CHONGQING GENRIX BIOPHARMACEUTICAL stocks are traded under the ticker 688443.
688443 stock has fallen by −3.15% compared to the previous week, the month change is a 2.22% rise, over the last year CHONGQING GENRIX BIOPHARMACEUTICAL has showed a −27.71% decrease.
We've gathered analysts' opinions on CHONGQING GENRIX BIOPHARMACEUTICAL future price: according to them, 688443 price has a max estimate of 40.07 CNY and a min estimate of 36.00 CNY. Watch 688443 chart and read a more detailed CHONGQING GENRIX BIOPHARMACEUTICAL stock forecast: see what analysts think of CHONGQING GENRIX BIOPHARMACEUTICAL and suggest that you do with its stocks.
688443 reached its all-time high on May 14, 2024 with the price of 45.51 CNY, and its all-time low was 22.11 CNY and was reached on Sep 24, 2024. View more price dynamics on 688443 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
688443 stock is 7.05% volatile and has beta coefficient of 1.72. Track CHONGQING GENRIX BIOPHARMACEUTICAL stock price on the chart and check out the list of the most volatile stocks — is CHONGQING GENRIX BIOPHARMACEUTICAL there?
Yes, you can track CHONGQING GENRIX BIOPHARMACEUTICAL financials in yearly and quarterly reports right on TradingView.
CHONGQING GENRIX BIOPHARMACEUTICAL is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
688443 net income for the last quarter is −184.41 M CNY, while the quarter before that showed −198.16 M CNY of net income which accounts for 6.94% change. Track more CHONGQING GENRIX BIOPHARMACEUTICAL financial stats to get the full picture.
No, 688443 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 547.00 employees. See our rating of the largest employees — is CHONGQING GENRIX BIOPHARMACEUTICAL on this list?
Like other stocks, 688443 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CHONGQING GENRIX BIOPHARMACEUTICAL stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CHONGQING GENRIX BIOPHARMACEUTICAL technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CHONGQING GENRIX BIOPHARMACEUTICAL stock shows the strong sell signal. See more of CHONGQING GENRIX BIOPHARMACEUTICAL technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.